Nyxoah Announces Reduction of the Maximum Amount Available Under its At the-Market Equity Offering Program
May 22 2024 - 4:10PM
REGULATED
INFORMATIONINSIDE INFORMATION
Nyxoah Announces Reduction of the Maximum
Amount Available Under its At-the-Market Equity Offering
Program
Mont-Saint-Guibert, Belgium – May 22,
2024, 10:10pm CET / 4:10pm ET – Nyxoah SA (Euronext
Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a
medical technology company focused on the development and
commercialization of innovative solutions to treat Obstructive
Sleep Apnea (OSA), announced today that it has reduced the maximum
amount of 6,000,000 ordinary shares available for issuance under
its “at-the-market” offering (announced on December 22, 2022) by an
amount of 1,569,139 ordinary shares, or share capital of
EUR 269,579 (excluding issuance premium), resulting in
(i) a maximum of 4,430,861 ordinary shares to be issued under
its “at-the-market” offering, of which 3,662,699 ordinary shares
remain available for issuance, and (ii) an increase of the
authorized capital that is available to the board of directors by
EUR 269,579. For further context, please refer to
section 1.5.2 of the May 22, 2024 board report that is
available on the investor page of Nyxoah’s website
(https://investors.nyxoah.com/financials > Special Reports).
This press release shall not constitute an offer
to sell or a solicitation of an offer to buy any securities of the
Company.
About NyxoahNyxoah is a medical
technology company focused on the development and commercialization
of innovative solutions to treat OSA. Nyxoah’s lead solution is the
Genio® system, a patient-centered, leadless and battery-free
hypoglossal neurostimulation therapy for OSA, the world’s most
common sleep disordered breathing condition that is associated with
increased mortality risk and cardiovascular comorbidities. Nyxoah
is driven by the vision that OSA patients should enjoy restful
nights and feel enabled to live their life to its
fullest.
Caution – CE marked since 2019.
Investigational device in the United States. Limited by U.S.
federal law to investigational use in the United States.
Forward-Looking StatementsThis
press release contains forward-looking statements, which are made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. All statements that are not
statements of historical facts are, or may be deemed to be,
forward-looking statements. Such forward-looking statements may be
identified by words such as “expects,” “potential,” “could,” or
similar expressions that are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words. Forward-looking statements include express
or implied statements relating to, among other things, Nyxoah’s
current expectations regarding the Genio® system; planned and
ongoing clinical studies of the Genio® system; the potential
advantages of the Genio® system; Nyxoah’s goals with respect to the
development, regulatory pathway and potential use of the Genio®
system; the utility of clinical data in potentially obtaining FDA
approval of the Genio® system; the Company's results of operations,
financial condition, liquidity, performance, prospects, growth and
strategies; and statements relating to the offering, including the
expected closing, the anticipated proceeds from the offering and
the use thereof. These statements are neither promises nor
guarantees and are subject to a variety of risks and uncertainties,
many of which are beyond Nyxoah’s control, which could cause actual
results to differ materially from those contemplated in these
forward-looking statements. In particular, these risks and
uncertainties include, without limitation, risks relating to market
conditions and the Company’s inability, or the inability of the
underwriters, to satisfy the conditions for the closing of the
offering. Given these uncertainties, the reader is advised not to
place any undue reliance on such forward-looking statements. Other
risks and uncertainties faced by Nyxoah include those identified
under the heading "Risk Factors" in Nyxoah’s most recent Annual
Report on Form 20-F filed with the SEC, as well as subsequent
filings and reports filed with the SEC. The forward-looking
statements contained in this press release reflect Nyxoah’s views
as of the date hereof, and Nyxoah does not assume and specifically
disclaims any obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as may be required by law.
Contact:NyxoahDavid DeMartino,
Chief Strategy OfficerIR@nyxoah.com
- 2. ENGLISH_ATM Reduction Press Release - May 2024
Nyxoah (NASDAQ:NYXH)
Historical Stock Chart
From Sep 2024 to Oct 2024
Nyxoah (NASDAQ:NYXH)
Historical Stock Chart
From Oct 2023 to Oct 2024